[Cardiotoxicity from anti-HER-2 therapies in patients with HER-2 positive breast cancer].

Background: HER-2 positive (+) breast cancer (BC) accounts for 20-25% of BC, it is more aggressive, and it has a lower survival rate. Since the approval of trastuzumab in 1998, other HER-2-targeted therapies such as pertuzumab and trastuzumab emtansine (TDM1) have been introduced, improving patient survival. However, cardiotoxicity is an adverse effect of these treatments.

[Returning to work after diagnosis and treatment of breast cancer].

Background: Returning to work and performing housework tasks (HWT) is the final step in overcoming breast cancer (BC).

Objective: To assess whether clinical characteristics and type of treatment impact employment status and performance of HWT.

Material And Methods: A total of 119 patients diagnosed with early BC were enrolled.

[Adherence to adjuvant hormonal therapy in patients with breast cancer].

Background: Adherence to hormonal therapy (HT) treatment is a complex and multifaceted issue that can determine variations in response to treatment. However, it is little known about it in routine clinical practice.

Objective: To assess adherence to HT from 1 to 5 years of 190 patients treated at the (in Montevideo, Uruguay), and to identify factors for the interruption of therapy.